



December 11, 2018

Listing Department BSE LIMITED P J Towers, Dalal Street, Fort, Mumbai–400 001

Code: 532 321

Listing Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), <u>Mumbai-400 051</u>

Code: CADILAHC

Re.: Press Release.

Dear Sir / Madam,

Please find enclosed a copy of press release dated December 11, 2018 titled "Liva Pharmaceuticals receives approval from the USFDA for its supplemental abbreviated new drug application (sANDA), Ranitidine Injection USP".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,


Yours faithfully, For, CADILA HEALTHCARE LIMITED

~ **UPEN H. SHAH**

COMPANY SECRETARY

Encl.: As above





Liva Pharmaceuticals receives approval from the USFDA for its supplemental abbreviated new drug application (sANDA), Ranitidine Injection USP Ahmedabad, December 11, 2018

Liva Pharmaceuticals Limited, a wholly-owned subsidiary company of Cadila Healthcare Limited has received the approval from the USFDA for its supplemental abbreviated new drug application (sANDA), Ranitidine Injection USP, 25 mg/mL, 2 mL Single dose vials and 6 mL Multi-dose vials. It will be manufactured at Liva Pharma's manufacturing facility at Vadodara and is the first product to be approved from this site for marketing in the US.

Ranitidine belongs to the class of medications called H2-antagonists and is used to treat stomach and duodenal (intestinal) ulcers, and prevent them from recurring. It is also used to treat gastroesophageal reflux disease (GERD) and Zollinger-Ellison Syndrome. The injectable form of ranitidine is given for short-term treatment of these conditions when a patient is unable to take this medication orally.

The group now has 237 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
